Sucralfate is an anti-ulcer medication used to treat acid-related stomach conditions, such as ulcers and gastroesophageal reflux disease (GERD). It is available in oral tablet and suspension forms, and is typically taken once or twice daily. While it is generally a safe and effective medication, there are some potential side effects that doctors should be aware of when prescribing it to their patients. In this article, we will discuss the hidden side effects of sucralfate and how to manage them.
The most common side effects of sucralfate include nausea, vomiting, diarrhea, constipation, headache, and dizziness. These side effects are usually mild and do not require medical attention unless they become severe or do not go away. It is important to note that these side effects are more likely to occur if the medication is taken on an empty stomach.
Less common side effects of sucralfate include stomach pain, gas, indigestion, and a metallic taste in the mouth. These side effects are usually mild and do not require medical attention unless they become severe or do not go away. It is important to note that these side effects are more likely to occur if the medication is taken on an empty stomach.
Rare side effects of sucralfate include rash, hives, itching, difficulty breathing, chest tightness, swelling of the face, lips, tongue, or throat, and hoarseness. If any of these side effects occur. It is important to note that these side effects are more likely to occur if the medication is taken on an empty stomach.
Sucralfate is a safe and effective medication for treating acid-related stomach conditions. However, it can cause side effects, including nausea, vomiting, diarrhea, constipation, headache, and dizziness. If you experience any of the rare side effects, such as rash, hives, itching, difficulty breathing, chest tightness, swelling of the face, lips, tongue, or throat, or hoarseness.
1.
Breast Cancer Patients Living Longer Post-Medicaid Expansion
2.
Error on the MGUS-Autoimmune Disease Association.
3.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
4.
The majority of cancer medications that receive expedited approval end up failing confirmatory trials.
5.
Unified Neuro/Psych Residency Program: New Proposal.
1.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
2.
Hemoglobin C: Understanding its Role in Sickle Cell Disease
3.
Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging
4.
Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer
5.
The Growing Challenge of Haematological Malignancies in Older Adults
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
4.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation